Limits...
Prostate Tumor Overexpressed 1 (PTOV1) Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Poor Survival Outcomes.

Yang Q, Lin H, Wu S, Lei F, Zhu X, Song L, Hong M, Guo L - PLoS ONE (2015)

Bottom Line: Patients with a higher PTOV1 expression had shorter overall survival compared with those with a lower PTOV1 expression level, especially in lower N stage patients.Our data demonstrated that PTOV1 overexpression is associated with poor survival outcomes of NPC patients, especially in N0-1 patients.Hence, PTOV1 may help to detect early lymph node metastasis of NPC patients and serve as an independent prognostic biomarker for human NPC.

View Article: PubMed Central - PubMed

Affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P.R. China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P.R. China.

ABSTRACT

Background: Prostate tumor overexpressed 1 (PTOV1) has been reported to contribute to increased cancer proliferation. However, the clinical significance of PTOV1 in the development and progression of nasopharyngeal carcinoma (NPC) is unclear. Our study aimed to investigate the expression pattern of PTOV1 in NPC and its correlation with clinicopathological features of patients.

Methods: Western blotting and real-time PCR were conducted to examine PTOV1 expression levels in NPC cell lines and biopsy tissues compared with normal controls. Immunohistochemistry (IHC) was performed to analyze PTOV1 protein expression in paraffin-embedded tissues from 123 patients. Statistical analyses were applied to evaluate the clinical significance of PTOV1 expression.

Results: PTOV1 mRNA and protein levels were upregulated in NPC cell lines and clinical samples. IHC analyses showed that PTOV1 was highly expressed in 68 (55.3%) of 123 NPC specimens. Statistical analysis revealed that PTOV1 expression was significantly correlated with clinical stage (P < 0.001), T classification (P = 0.042) and N classification (P = 0.001). Patients with a higher PTOV1 expression had shorter overall survival compared with those with a lower PTOV1 expression level, especially in lower N stage patients. Multivariate analyses suggested that PTOV1 expression was an independent prognostic marker for survival in NPC patients.

Conclusions: Our data demonstrated that PTOV1 overexpression is associated with poor survival outcomes of NPC patients, especially in N0-1 patients. Hence, PTOV1 may help to detect early lymph node metastasis of NPC patients and serve as an independent prognostic biomarker for human NPC.

No MeSH data available.


Related in: MedlinePlus

The expression of PTOV1 protein in archived NPC tissues from patients at different clinical stages.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4549246&req=5

pone.0136448.g003: The expression of PTOV1 protein in archived NPC tissues from patients at different clinical stages.

Mentions: To further demonstrate that PTOV1 protein is overexpressed in clinical samples of NPC, we performed immunohistochemistry (IHC) staining of paraffin-embedded archived biopsies (123 NPC samples and three normal nasopharyngeal epithelial samples). Consistent with the results above, no signals were detected in the normal nasopharyngeal epithelial tissues, while strong expression was observed in the tumor cells of NPC samples (Fig 3). Among 123 samples, high levels of PTOV1 expression were detected in 68 samples (55.3%) and weak or no staining was observed in 55 tumor samples (44.7%, Table 1). Expression of PTOV1 could be detected both in the nucleus and the cytoplasm of carcinomatous cells (Fig 3). Furthermore, Quantitative analysis revealed that the mean optical density (MOD) of PTOV1 staining in NPC samples increased with advancing clinical stage (P < 0.05, S1 Fig), indicating that PTOV1 expression in NPC increased with advancing clinical stage.


Prostate Tumor Overexpressed 1 (PTOV1) Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Poor Survival Outcomes.

Yang Q, Lin H, Wu S, Lei F, Zhu X, Song L, Hong M, Guo L - PLoS ONE (2015)

The expression of PTOV1 protein in archived NPC tissues from patients at different clinical stages.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4549246&req=5

pone.0136448.g003: The expression of PTOV1 protein in archived NPC tissues from patients at different clinical stages.
Mentions: To further demonstrate that PTOV1 protein is overexpressed in clinical samples of NPC, we performed immunohistochemistry (IHC) staining of paraffin-embedded archived biopsies (123 NPC samples and three normal nasopharyngeal epithelial samples). Consistent with the results above, no signals were detected in the normal nasopharyngeal epithelial tissues, while strong expression was observed in the tumor cells of NPC samples (Fig 3). Among 123 samples, high levels of PTOV1 expression were detected in 68 samples (55.3%) and weak or no staining was observed in 55 tumor samples (44.7%, Table 1). Expression of PTOV1 could be detected both in the nucleus and the cytoplasm of carcinomatous cells (Fig 3). Furthermore, Quantitative analysis revealed that the mean optical density (MOD) of PTOV1 staining in NPC samples increased with advancing clinical stage (P < 0.05, S1 Fig), indicating that PTOV1 expression in NPC increased with advancing clinical stage.

Bottom Line: Patients with a higher PTOV1 expression had shorter overall survival compared with those with a lower PTOV1 expression level, especially in lower N stage patients.Our data demonstrated that PTOV1 overexpression is associated with poor survival outcomes of NPC patients, especially in N0-1 patients.Hence, PTOV1 may help to detect early lymph node metastasis of NPC patients and serve as an independent prognostic biomarker for human NPC.

View Article: PubMed Central - PubMed

Affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, P.R. China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P.R. China.

ABSTRACT

Background: Prostate tumor overexpressed 1 (PTOV1) has been reported to contribute to increased cancer proliferation. However, the clinical significance of PTOV1 in the development and progression of nasopharyngeal carcinoma (NPC) is unclear. Our study aimed to investigate the expression pattern of PTOV1 in NPC and its correlation with clinicopathological features of patients.

Methods: Western blotting and real-time PCR were conducted to examine PTOV1 expression levels in NPC cell lines and biopsy tissues compared with normal controls. Immunohistochemistry (IHC) was performed to analyze PTOV1 protein expression in paraffin-embedded tissues from 123 patients. Statistical analyses were applied to evaluate the clinical significance of PTOV1 expression.

Results: PTOV1 mRNA and protein levels were upregulated in NPC cell lines and clinical samples. IHC analyses showed that PTOV1 was highly expressed in 68 (55.3%) of 123 NPC specimens. Statistical analysis revealed that PTOV1 expression was significantly correlated with clinical stage (P < 0.001), T classification (P = 0.042) and N classification (P = 0.001). Patients with a higher PTOV1 expression had shorter overall survival compared with those with a lower PTOV1 expression level, especially in lower N stage patients. Multivariate analyses suggested that PTOV1 expression was an independent prognostic marker for survival in NPC patients.

Conclusions: Our data demonstrated that PTOV1 overexpression is associated with poor survival outcomes of NPC patients, especially in N0-1 patients. Hence, PTOV1 may help to detect early lymph node metastasis of NPC patients and serve as an independent prognostic biomarker for human NPC.

No MeSH data available.


Related in: MedlinePlus